FCMI
NDRM

Foresite Capital Management III’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Foresite Capital Management III’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-201,469
Closed -$3.27M – 21
2016
Q2 		$3.27M Sell
201,469
-90,902
-31% -$1.53M 2.25% 9
2016
Q1 		$4.13M Buy
292,371
+30,426
+12% +$411K 3.19% 11
2015
Q4 		$4.47M Buy
+261,945
New +$5.1M 3.96% 12

Other funds holding NDRM

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Foresite Capital Management III's NDRM Position: Q3 2016 in Review

Foresite Capital Management III sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q3 2016, closing a stake of 201,469 shares — an estimated $3.27M sold.

Foresite Capital Management III first reported a position in NDRM in Q4 2015 and held it in 3 quarters. The position peaked at $4.47M in Q4 2015. 50 funds tracked by Wall St. Rank hold NDRM as of Q3 2016.

  • Foresite Capital Management III reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q3 2016 after selling out during the quarter.
  • Foresite Capital Management III sold 201,469 NeuroDerm Ltd. Ordinary Shares shares in Q3 2016, an estimated $3.27M.
  • Foresite Capital Management III first reported a position in NeuroDerm Ltd. Ordinary Shares in Q4 2015 and held it in 3 quarters.
  • Foresite Capital Management III's NeuroDerm Ltd. Ordinary Shares position peaked at $4.47M in Q4 2015.
  • 50 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q3 2016.

Based on Foresite Capital Management III's 13F filing for Q3 2016, filed 14 Nov 2016.